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Accepted 29 June 2013AbstractObjective: To determine the prevalence of preexisting antibodies against the pandemic 2009 Influenza A (H1N1) virus in pregnant women and to
evaluate the seroprotection of the mothers and infants by a single injection of monovalent vaccine during the pandemic.
Materials and Methods: Seropositivity rate of H1N1 among the nonvaccinated were compared with the vaccinated women. A single dose of
vaccine, either nonadjuvanted AdimFlu-S or MF59-adjuvanted vaccine, was injected to the voluntarily vaccinated group. Maternal and cord
blood sera were collected to evaluate the antibody response of the H1N1 virus. Seropositivity was defined as a hemagglutination inhibition titer
to H1N1 (A/Taiwan/126/09) 1:40.
Results: A total of 210 healthy, singleton, pregnant women were enrolled between January 2010 and May 2010. Seropositivity (1:40) of
maternal hemagglutination inhibition was significantly higher in the vaccinated group (78%) than the nonvaccinated group (9.5%); 41.6% (20/
48) of seropositive titers were >1:80. In nine vaccinated cases resulting in negative serum titers (<1:40), the prevalence of negative titer in the
women received AdimFlu-S (14.8%, 4/31) was lower ( p ¼ 0.025) than those received MF59-adjuvanted vaccine (50%, 5/10).
Conclusions: Subclinical infection against H1N1 was low in Taiwanese pregnant women in the pandemic 2009. Seropositivity >75% could be
achieved in the paired maternal and cord serum samples by a single injection of monovalent H1N1 vaccine.
Copyright  2013, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Influenza virus is a highly contagious respiratory pathogen
that can cause severe illness. Influenza virus infects all age
groups, but it is especially an important cause of hospitaliza-
tion and mortality in early infancy. Pregnant women are also* Corresponding author. Department of Obstetrics and Gynecology, Chang
Gung Memorial Hospital Linkou Medical Center, 5 Fushin Street, Guishan,
Taoyuan 333, Taiwan.
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http://dx.doi.org/10.1016/j.tjog.2013.06.002vulnerable to the serious sequelae of influenza infections of
the respiratory tract, including systemic complications
affecting the heart, brain, liver, kidney, muscle, and even death
[1,2].
In April 2009, a new influenza A virus H1N1, was identi-
fied in the outbreaks of respiratory illness in Mexico. On June
11, 2009, the World Health Organization declared a worldwide
pandemic [3e7]. In Taiwan, the first H1N1 virus-infected case
was confirmed on May 20, and the first fatal case was reported
on July 31, 2009. Over a thousand cases have been reported to
the Center for Disease Control (CDC)-Taiwan since then.cs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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severity of H1N1 is reported to be higher in pregnant women,
leading to a three times higher hospitalization rate than
nonpregnant women [8,9].
Understanding the seasonal nature of human influenza and
its potential modes of transmission [10,11] is critical for its
prevention and control. The World Health Organization sug-
gested a priority of H1N1 vaccination, which has been indi-
vidually modified by countries worldwide. Considering that
pregnant women have higher risks of morbidity and mortality
[8], the CDC-Taiwan announced the priority of vaccinating
pregnant women and infants. Two H1N1 vaccines have been
used in Taiwan since November 2009, including a monovalent
MF59-adjuvanted vaccine (Novartis Vaccines and Diagnostics,
Sovicille, Italy) and AdimFlu-S, unadjuvanted, inactivated,
split-virus vaccine (Adimmune Corporation, Taichung,
Taiwan). Although several cases of fetal loss shortly after the
vaccination were reported in pregnant women [8,12], results of
extensive studies indicated that H1N1 vaccination during
pregnancy did not increase maternal and fetal adverse events
[8,12e15]. However, studies of the seroresponse in vaccinated
mothers and their infants were incomplete and should be
clarified in different ethnic groups [11,16e18].
The aim of this study was to understand the prevalence of
pre-existing antibodies against the pandemic 2009 Influenza A
(H1N1) virus in pregnant women and to evaluate the sero-
protection of the mothers and infants by a single vaccination of
monovalent vaccine during the 2009 pandemic.
Participants and methodsPatientsThis is a prospective surveillance study of a consecutive
cohort of 210 healthy, singleton, pregnant women who had
regular prenatal visits and gave birth between January 2010
and May 2010. These women were asked if they had received
H1N1 vaccination during their pregnancy, at least 21 days
prior to the delivery. The exclusion criteria for participants
were a history of systemic diseases, preterm delivery,
congenital anomaly, and hypersensitivity or severe allergy, any
episode of respiratory diseases, and blood transfusion or sea-
sonal flu vaccination in the past 3 months. Both maternal
peripheral blood and cord blood were obtained for serologic
tests for the H1N1 virus at term delivery. The infants were
followed up at age 2 months and 6 months in the pediatric
clinic or by questionnaires and phone calls.
This protocol and informed consent forms were reviewed
and approved by Institution Review Board of Chang Gung
Memorial Hospital (CGMH IRB No. 98-3686B). Only women
who signed informed consent forms were enrolled in this
study.VaccinesThe H1N1 virus vaccines used in this study were provided
by the CDC-Taiwan for the pregnant women in a nationwidevaccination campaign. The nonadjuvanted AdimFlu-S
(Adimmune Corporation, Taichung, Taiwan) contains 15 mg
of the A/California/7/2009 (H1N1)-hemagglutinin antigen,
and MF59-adjuvanted vaccine contains 7.5 mg of A/H1N1/
California/7/2009 strain influenza antigen. A single dose of
vaccine was injected to individuals in the vaccinated group.
Both vaccines were randomly distributed by the nationwide
H1N1 vaccination program.Hemagglutination inhibition assayThe antibody responses to the H1N1 (A/Taiwan/126/09)
virus were detected by the hemagglutination inhibition (HI)
assay using the previously reported method [19]. Each serum
sample was treated with a receptor-destroying enzyme (RDE;
Sigma-Aldrich, St Louis, MO, USA) to inactivate nonspecific
inhibitors. All samples were tested in duplicate at an initial
dilution of 1:10 to a final dilution of 1:640. Positive control
serum was obtained from a patient with a laboratory-
confirmed H1N1 infection (reverse transcriptionepolymerase
chain reaction positive) at the convalescent stage in Chang
Gung Memorial Hospital. Both seropositivity and seropro-
tection were defined as complete inhibition of agglutination at
1:40 dilution of serum to H1N1.Statistical analysisIn this study, antibody titer 1:40 was defined as positive
whereas <1:40 as negative. The difference between the posi-
tive and negative groups was tested with Chi-square test or
Fisher’s exact test whenever applicable. All analyses were
carried out using SPSS version 17.0 (SPSS Inc., Chicago, IL,
USA). Two-tailed p < 0.05 were considered statistically
significant.
Results
A total of 210 maternaleinfant pairs were collected. Two
infants did not come back for the follow-up at 6-month-old.
Forty-one participants (20.0%) received monovalent H1N1
vaccines: 31 with nonadjuvant AdimFlu-S and 10 with MF59-
adjuvanted vaccine. Fifteen participants were vaccinated in the
first trimester, 17 in the second trimester, and nine in the third
trimester.
The demographic data of the enrolled cases are summarized
in Table 1. Maternal ages, gestational ages, newborn body
weights, and delivery modes were not different between the
vaccinated and nonvaccinated groups. Two facial clefts and a
congenital diaphragmatic hernia were diagnosed prenatally in
the nonvaccinated group, and all babies have been doing well
after surgical repairs.
Summarized in Table 2, seropositivity (1:40) of maternal
hemagglutination inhibition was significantly higher in the
vaccinated group (78%) than the nonvaccinated group (9.5%);
41.6% (20/48) of seropositive titers were >1:80. In nine
vaccinated cases resulting in negative serum titers (<1:40), the
prevalence of negative titer in the women received AdimFlu-S
Table 3
Seropositivity of cord blood hemagglutination inhibition (HI) titers in vacci-
nated and nonvaccinated groups
Vaccination HI titer
<1:40 1:40 p
Yes (n ¼ 41) 10 (24.4) 31 (75.6) <0.0001
No (n ¼ 169) 154 (91.1) 15 (8.9)
Data are presented as n (%).
Table 1






Maternal age (y) 31.0  4.0 31.0  4.5 NS
Gestational age (wk) 39.0  1.1 39.0  1.3 NS
Newborn body
weight (g)
3137  388 3138  350 NS
Cesarean section 3 (7.3) 11 (6.5) NS
Vaginal delivery 38 (92.7) 158 (93.5) NS
Newborn anomaly None Diaphragmatic
hernia (n ¼ 1),
Facial cleft
(n ¼ 2)
Data are presented as mean  SD or n (%). NS ¼ not statistically significant;
SD ¼ standard deviation.
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received the MF59-adjuvanted vaccine (50%, 5/10). Although
classified as negative serum titers (<1:40), four cases (12.9%,
4/31) receiving nonadjuvant AdimFlu-S, and three cases (30%,
3/10) receiving MF59-adjuvanted vaccine had titers of 1:20.
All cord blood, except two described as follows, had
seropositivity identical to the corresponding maternal blood
(Table 3). In the AdimFlu-S vaccinated group, the cord blood
sample with materno-cord discrepancy had an antibody titer of
1:20. In the nonvaccinated group, the cord blood sample with
materno-cord discrepancy had an antibody titer of 1:10.
Medical chart reviewing and telephone following up at 2
months and 6 months after birth indicated none of the infants
in the vaccinated group had febrile attacks or fever-related
admission within the first 6 months of life. In the 16 sero-
positive cases of nonvaccinated pregnant women, no mothers
or infants were reported with influenza-like illness or related
admission up to 6 months of postpartum follow-up.
Discussion
Maternal immunization is a useful protection against
influenza in infants of early life, because antibody can be
transferred from the mother to the fetus through the placenta,
colostrum, and milk. Both pregnant women and young infants
were found to be vulnerable to a serious sequelae of influenza
infection. Immunization of pregnant women offers the theo-
retical advantage of endowing the fetus with maternal anti-
body prior to delivery, delaying the onset and decreasing the
severity of influenza disease in young infants [10,11,20]. No
increased risks for maternal or fetal complication were iden-
tified in vaccinated pregnant women [11e15]. However,Table 2




Yes (n ¼ 41) 9 (22.0) 32 (78.0) <0.0001
No (n ¼ 169) 153 (90.5) 16 (9.5)
Data are presented as n (%).limited serological data of seasonal influenza or H1N1 vac-
cines in pregnancy and infant period were reported in Asia
[17,21].
The H1N1 virus will probably continue to circulate around
the world for years to come. It is necessary to provide up-to-
date scientific data for our public education. Inactivated
influenza vaccine is currently recommended by the US CDC
(Centers for Disease Control and Prevention in Atlanta,
Georgia, USA) for all pregnant women, including in the first
trimester during influenza seasons or those with high risks
[14,19,22]. However, safety issues still remain a major barrier
in obstetric practice.
The H1N1 vaccines (AdimFlu-S or MF59-adjuvanted
vaccine) were injected to more than five million people in
Taiwan, estimated to about 25% of the total population from
2009 to 2010 [22]. No pregnant women enrolled in this study
had serious adverse vaccine related events, but the vaccination
rates in the pregnant women were still low, such as the 20% in
this study.
A serum HI titer of 1:40 is shown to be protective against
H1N1 and thus used as a cut-off value for evaluating the
immunogenicity of influenza vaccines [23]. In this study, more
than 75% of paired maternal-fetal sera had serum HI titers of
1:40 after a single HIN1 vaccination. The vaccines used in
this study fulfilled the immunogenicity criteria for influenza
vaccines used in healthy adults aged 18e60 years: serocon-
version in >40% and/or seroprotection in >70% of vaccinated
persons and/or increase of geometric mean titer of HI  2.5
for each virus strain, which are recommended by the European
Agency for the Evaluation of Medicinal Products/Committee
for Proprietary Medicinal Products [24].
The prevalence of preexisting antibody against H1N1 virus
varies among different age groups. Taking the data of Taiwan
as an example, 8% were seropositive in the younger people
aged 22e60 years, whereas about 40% were positive in the
elderly [19,22]. After the pandemic, the overall seroconversion
rate was increased to approximately 30% in the whole popu-
lation and 20% in the unimmunized population [19,22]. Of
note, the prevalence of preexisting positive antibody titer was
not increased in the nonvaccinated pregnant women (9.5%)
during the pandemics.
Passively acquired serum antibody titers can persist in most
infants for at least 5 months [16]. In the vaccinated pregnant
women of this study, there was no reported case of mother or
infant that suffered from influenza-like hospital admission.
The efficacy of the two monovalent H1N1 vaccines did not
show a statistical difference. However, the limitations of this
359A. Chao et al. / Taiwanese Journal of Obstetrics & Gynecology 52 (2013) 356e359study include: (1) lack of a randomized control group; (2) a
small number of mothers received the H1N1 vaccine; and (3)
only one pair of blood samples was collected at the time of
delivery, not in a longitudinal surveillance study fashion.
In conclusion, this report revealed that the rate of subclinical
infection or the seroprevalence of the novel influenza virus
among pregnant mothers prior to vaccination was 9.5%. Only
20% of this susceptible group received voluntary vaccination. A
single dose of the monovalent vaccine, either AdimFlu-S or
MF59-adjuvanted vaccine, could result in seroconversion of
more than 75% of the pregnant women and their infants. Results
of this study favor the addition of influenza vaccination to a
previously proposed list of perinatal vaccinations [25].
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